FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2531349882> ?p ?o ?g. }

• W2531349882 endingPage "4504" @default.
• W2531349882 startingPage "4493" @default.
• W2531349882 abstract "A phase I+II clinical trial of vaccination with MAGE‑A4 protein complexed with cholesteryl pullulan melanoma antigen gene-A4 nanogel (CHP-MAGE-A4) is currently underway in patients with MAGE‑A4‑expressing cancer. In the present study, the primary phase I endpoint was to test the safety of the administration of 300 µg CHP‑MAGE‑A4 with and without OK‑432. Another aim of the study was to clarify the details of the specific humoral immune response to vaccination. The 9 patients enrolled for phase I were vaccinated 6 times, once every 2 weeks: 3 patients with 100 µg and 3 patients with 300 µg CHP‑MAGE‑A4, and 3 patients with 300 µg CHP‑MAGE‑A4 plus 0.5 clinical units of OK‑432. Toxicities were assessed using Common Terminology Criteria for Adverse Events v3.0. Clinical response was evaluated by modified Response Evaluation Criteria in Solid Tumours. Immunological monitoring of anti‑MAGE‑A4‑specific antibodies was performed by ELISA of pre‑ and post‑vaccination patient sera. The 6 vaccinations produced no severe adverse events. Stable disease was assessed in 4/9 patients. Anti‑MAGE‑A4 total immunoglobulin (Ig)G titers increased in 7/9 patients. Efficacious anti‑MAGE‑A4 IgG1, 2 and 3 antibody responses were observed in 7/9 patients. Among them, positive conversions to T helper 2 (Th2)‑type antibody responses (IgG4 and IgE) were observed after frequent vaccination in 4/7 patients. The Th2 conversion was possibly associated with undesirable clinical observations, including progressive disease and the appearance of a new relapse lesion. The present study suggested that frequent vaccinations activated a Th2‑dominant status in the cancer patients. The identification of a time‑dependent IgG subclass and IgE antibody production during vaccination protocols may be a useful surrogate marker indicating a potentially undesirable change of the immunological environment for an effective antitumor immune response in cancer patients." @default.
• W2531349882 created "2016-10-21" @default.
• W2531349882 creator A5000192888 @default.
• W2531349882 creator A5010271161 @default.
• W2531349882 creator A5015140598 @default.
• W2531349882 creator A5019726140 @default.
• W2531349882 creator A5023039953 @default.
• W2531349882 creator A5023441759 @default.
• W2531349882 creator A5031288222 @default.
• W2531349882 creator A5043612020 @default.
• W2531349882 creator A5052504412 @default.
• W2531349882 creator A5053550345 @default.
• W2531349882 creator A5055684381 @default.
• W2531349882 creator A5067458112 @default.
• W2531349882 creator A5080996823 @default.
• W2531349882 creator A5090915905 @default.
• W2531349882 date "2016-10-13" @default.
• W2531349882 modified "2023-10-14" @default.
• W2531349882 title "Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene-A4 nanogel" @default.
• W2531349882 cites W1490916211 @default.
• W2531349882 cites W1580895178 @default.
• W2531349882 cites W1946960193 @default.
• W2531349882 cites W1965504034 @default.
• W2531349882 cites W1965536515 @default.
• W2531349882 cites W1970692246 @default.
• W2531349882 cites W1973364140 @default.
• W2531349882 cites W1979102191 @default.
• W2531349882 cites W1991168811 @default.
• W2531349882 cites W1992699637 @default.
• W2531349882 cites W1993946895 @default.
• W2531349882 cites W2020157495 @default.
• W2531349882 cites W2034885195 @default.
• W2531349882 cites W2076668534 @default.
• W2531349882 cites W2083408248 @default.
• W2531349882 cites W2091490823 @default.
• W2531349882 cites W2096494798 @default.
• W2531349882 cites W2096555825 @default.
• W2531349882 cites W2097665279 @default.
• W2531349882 cites W2098149634 @default.
• W2531349882 cites W2100158834 @default.
• W2531349882 cites W2101939433 @default.
• W2531349882 cites W2102722090 @default.
• W2531349882 cites W2112670248 @default.
• W2531349882 cites W2114491909 @default.
• W2531349882 cites W2129683253 @default.
• W2531349882 cites W2131638796 @default.
• W2531349882 cites W2137088550 @default.
• W2531349882 cites W2144667537 @default.
• W2531349882 cites W2149532361 @default.
• W2531349882 cites W2156040418 @default.
• W2531349882 cites W2164155579 @default.
• W2531349882 cites W2164836148 @default.
• W2531349882 cites W2165835640 @default.
• W2531349882 cites W2167739507 @default.
• W2531349882 cites W2560367415 @default.
• W2531349882 cites W4291980590 @default.
• W2531349882 doi "https://doi.org/10.3892/ol.2016.5253" @default.
• W2531349882 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5228337" @default.
• W2531349882 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28105158" @default.
• W2531349882 hasPublicationYear "2016" @default.
• W2531349882 type Work @default.
• W2531349882 sameAs 2531349882 @default.
• W2531349882 citedByCount "24" @default.
• W2531349882 countsByYear W25313498822016 @default.
• W2531349882 countsByYear W25313498822018 @default.
• W2531349882 countsByYear W25313498822019 @default.
• W2531349882 countsByYear W25313498822020 @default.
• W2531349882 countsByYear W25313498822021 @default.
• W2531349882 countsByYear W25313498822022 @default.
• W2531349882 countsByYear W25313498822023 @default.
• W2531349882 crossrefType "journal-article" @default.
• W2531349882 hasAuthorship W2531349882A5000192888 @default.
• W2531349882 hasAuthorship W2531349882A5010271161 @default.
• W2531349882 hasAuthorship W2531349882A5015140598 @default.
• W2531349882 hasAuthorship W2531349882A5019726140 @default.
• W2531349882 hasAuthorship W2531349882A5023039953 @default.
• W2531349882 hasAuthorship W2531349882A5023441759 @default.
• W2531349882 hasAuthorship W2531349882A5031288222 @default.
• W2531349882 hasAuthorship W2531349882A5043612020 @default.
• W2531349882 hasAuthorship W2531349882A5052504412 @default.
• W2531349882 hasAuthorship W2531349882A5053550345 @default.
• W2531349882 hasAuthorship W2531349882A5055684381 @default.
• W2531349882 hasAuthorship W2531349882A5067458112 @default.
• W2531349882 hasAuthorship W2531349882A5080996823 @default.
• W2531349882 hasAuthorship W2531349882A5090915905 @default.
• W2531349882 hasBestOaLocation W25313498821 @default.
• W2531349882 hasConcept C121608353 @default.
• W2531349882 hasConcept C126322002 @default.
• W2531349882 hasConcept C141105273 @default.
• W2531349882 hasConcept C147483822 @default.
• W2531349882 hasConcept C159654299 @default.
• W2531349882 hasConcept C197934379 @default.
• W2531349882 hasConcept C203014093 @default.
• W2531349882 hasConcept C22070199 @default.
• W2531349882 hasConcept C22889606 @default.
• W2531349882 hasConcept C2777701055 @default.
• W2531349882 hasConcept C2780868878 @default.
• W2531349882 hasConcept C32611913 @default.

• next